Weil Cornell or Mt Sini?
You can't patent genes but you can the method for finding them. BTX will rock the cancer establishment.
Take for example the Asthma Health app, a joint effort of Mount Sinai Icahn School of Medicine and LifeMap Solutions, a subsidiary of BioTime, Inc. Eric Schadt, a professor of genomics at the Icahn School who spearheaded the collaboration, told Digital Trends that by using the app, “over 3,500 people consented and enrolled in our research study in less than 72 hours! It would have taken us years to get 3,500 people enrolled the traditional way.”
Why Was It So Successful?
The new platform allows someone to partake in a clinical study from the comfort of his or her own house, for free.
DigitalTrends explained how these apps, particularly Asthma Health, work.
“Developed within the framework of Apple's ResearchKit, Asthma Health aims to revolutionize the way clinical studies are done. The app has multiple uses. On one hand, it teaches patients to self-monitor and stick to their treatment plans. ‘A message will pop up and say, ‘you set up your reminder for 5pm–-did you use your inhaler?’ says Yu-Feng Yvonne Chan, director of personalized medicine and digital health at Icahn Institute at Mount Sinai. When users tap the screen to confirm they’re in compliance, they get a smiley face, which Chan says should ‘promote positive behavioral changes and adherence to treatment plans.’
"On the other hand, Asthma Health can track patients’ symptoms, flare-ups, and the triggers that cause them, sending all that info to a database so researchers can devise personalized treatments. In the future, if a patient has a flare-up on a particular date in a particular location, the software would analyze the GPS data, weather, air quality, and other factors to identify a probable cause. ‘We would note the triggers on this particular date—heat, humidity, or source of pollution,’ Chan says. ‘We would see patterns emerging and hopefully would provide patents with personalized feedback—such as ‘you are sensitive to this location, try to avoid it.’”
MENLO PARK, Calif., March 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer, will ring The Opening Bell® of the New York Stock Exchange (NYSE) tomorrow, Thursday, March 5, 2015. Asterias began trading as an NYSE MKT listed company on October 8, 2014.
"New York Stock Exchange is a trusted partner to Asterias Biotherapeutics, and we are honored that the NYSE has invited our company to ring The Opening Bell," stated Mr. Lichtinger. "We believe our common stock listing on the NYSE MKT, the premier U.S. equities market for listing and trading of small growth companies, helps increase trading liquidity and provides greater exposure to a larger group of investors while increasing awareness of our promising therapeutic products that have the potential to address significant unmet medical needs using our stem cell technology platform. Our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury and AST-VAC2 for use in treating lung cancer, are both in the clinic, and we are focused on executing our strategic plan in order to further advance these two products through meaningful clinical milestones."
Mr. Lichtinger will be joined by members of the Company's Board of Directors and management team. The NYSE Opening Bell will ring at 9:30 a.m. Eastern time and can be viewed live on the NYSE's website.
Lookin good! Biotime a leader in stem cell, cancer and genome big data sector that are about merge leaving us the cream of the crop.
GEHC and BTX have a partnership for ESI cell lines for toxicity and assay use, nothing to do with cancer.
OncoCyte as far as I know has a foot in the door with Weill Cornell and some high profile cancer institutions in the EU, so you might want to look closer at their affiliations.
Upside as a result minimal, with BTX ip I'd say we are in for a continual uptrend throughout 2015.
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
December 15, 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, access to more biologically relevant and predictive cell models is becoming increasingly important. The agreement provides ESI with access to additional intellectual property and hence the ability to further expand its product portfolio bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research.
“The mission of BioTime’s ESI BIO division, which includes ES Cell International, is to sell high quality tools of regenerative medicine to the research product markets, and this licensing agreement will allow the company to provide superior products for clinical research and drug testing,” said Jeffrey Janus, ES Cell International’s CEO and BioTime’s VP of Sales and Marketing. “The ESI BIO business has the potential to generate near-term revenues for BioTime while simultaneously placing clinical grade cells, injectable matrices, and related components of a wide array of potential regenerative therapies into the hands of potential collaborators.”